203 related articles for article (PubMed ID: 28359814)
1. Targeted delivery of anticancer drugs to tumor vessels by use of liposomes modified with a peptide identified by phage biopanning with human endothelial progenitor cells.
Fukuta T; Asai T; Kiyokawa Y; Nakada T; Bessyo-Hirashima K; Fukaya N; Hyodo K; Takase K; Kikuchi H; Oku N
Int J Pharm; 2017 May; 524(1-2):364-372. PubMed ID: 28359814
[TBL] [Abstract][Full Text] [Related]
2. From phage display to nanoparticle delivery: functionalizing liposomes with multivalent peptides improves targeting to a cancer biomarker.
Gray BP; Li S; Brown KC
Bioconjug Chem; 2013 Jan; 24(1):85-96. PubMed ID: 23186007
[TBL] [Abstract][Full Text] [Related]
3. Peptide-conjugated nanoparticles for targeted imaging and therapy of prostate cancer.
Yeh CY; Hsiao JK; Wang YP; Lan CH; Wu HC
Biomaterials; 2016 Aug; 99():1-15. PubMed ID: 27209258
[TBL] [Abstract][Full Text] [Related]
4. Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery.
Lee TY; Lin CT; Kuo SY; Chang DK; Wu HC
Cancer Res; 2007 Nov; 67(22):10958-65. PubMed ID: 18006841
[TBL] [Abstract][Full Text] [Related]
5. Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy.
Takara K; Hatakeyama H; Kibria G; Ohga N; Hida K; Harashima H
J Control Release; 2012 Aug; 162(1):225-32. PubMed ID: 22728515
[TBL] [Abstract][Full Text] [Related]
6. A stabilized retro-inverso peptide ligand of transferrin receptor for enhanced liposome-based hepatocellular carcinoma-targeted drug delivery.
Tang J; Wang Q; Yu Q; Qiu Y; Mei L; Wan D; Wang X; Li M; He Q
Acta Biomater; 2019 Jan; 83():379-389. PubMed ID: 30395963
[TBL] [Abstract][Full Text] [Related]
7. Anti-neovascular therapy using novel peptides homing to angiogenic vessels.
Oku N; Asai T; Watanabe K; Kuromi K; Nagatsuka M; Kurohane K; Kikkawa H; Ogino K; Tanaka M; Ishikawa D; Tsukada H; Momose M; Nakayama J; Taki T
Oncogene; 2002 Apr; 21(17):2662-9. PubMed ID: 11965539
[TBL] [Abstract][Full Text] [Related]
8. A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor.
He X; Na MH; Kim JS; Lee GY; Park JY; Hoffman AS; Nam JO; Han SE; Sim GY; Oh YK; Kim IS; Lee BH
Mol Pharm; 2011 Apr; 8(2):430-8. PubMed ID: 21222482
[TBL] [Abstract][Full Text] [Related]
9. Effective delivery of an angiogenesis inhibitor by neovessel-targeted liposomes.
Katanasaka Y; Ida T; Asai T; Maeda N; Oku N
Int J Pharm; 2008 Aug; 360(1-2):219-24. PubMed ID: 18565703
[TBL] [Abstract][Full Text] [Related]
10. Applicability of anti-neovascular therapy to drug-resistant tumor: suppression of drug-resistant P388 tumor growth with neovessel-targeted liposomal adriamycin.
Shimizu K; Asai T; Fuse C; Sadzuka Y; Sonobe T; Ogino K; Taki T; Tanaka T; Oku N
Int J Pharm; 2005 May; 296(1-2):133-41. PubMed ID: 15885465
[TBL] [Abstract][Full Text] [Related]
11. Liposome-based glioma targeted drug delivery enabled by stable peptide ligands.
Wei X; Gao J; Zhan C; Xie C; Chai Z; Ran D; Ying M; Zheng P; Lu W
J Control Release; 2015 Nov; 218():13-21. PubMed ID: 26428462
[TBL] [Abstract][Full Text] [Related]
12. A novel vascular-targeting peptide for gastric cancer delivers low-dose TNFα to normalize the blood vessels and improve the anti-cancer efficiency of 5-fluorouracil.
Lu L; Li ZJ; Li LF; Shen J; Zhang L; Li MX; Xiao ZG; Wang JH; Cho CH
Peptides; 2017 Nov; 97():54-63. PubMed ID: 28970092
[TBL] [Abstract][Full Text] [Related]
13. Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase.
Kondo M; Asai T; Katanasaka Y; Sadzuka Y; Tsukada H; Ogino K; Taki T; Baba K; Oku N
Int J Cancer; 2004 Jan; 108(2):301-6. PubMed ID: 14639619
[TBL] [Abstract][Full Text] [Related]
14. Cancer antineovascular therapy with liposome drug delivery systems targeted to BiP/GRP78.
Katanasaka Y; Ishii T; Asai T; Naitou H; Maeda N; Koizumi F; Miyagawa S; Ohashi N; Oku N
Int J Cancer; 2010 Dec; 127(11):2685-98. PubMed ID: 20178102
[TBL] [Abstract][Full Text] [Related]
15. Effects of surface displayed targeting ligand GE11 on liposome distribution and extravasation in tumor.
Tang H; Chen X; Rui M; Sun W; Chen J; Peng J; Xu Y
Mol Pharm; 2014 Oct; 11(10):3242-50. PubMed ID: 25181533
[TBL] [Abstract][Full Text] [Related]
16. The antitumor activity of tumor-homing peptide-modified thermosensitive liposomes containing doxorubicin on MCF-7/ADR: in vitro and in vivo.
Wang C; Wang X; Zhong T; Zhao Y; Zhang WQ; Ren W; Huang D; Zhang S; Guo Y; Yao X; Tang YQ; Zhang X; Zhang Q
Int J Nanomedicine; 2015; 10():2229-48. PubMed ID: 25834435
[TBL] [Abstract][Full Text] [Related]
17. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.
Zhang YF; Wang JC; Bian DY; Zhang X; Zhang Q
Eur J Pharm Biopharm; 2010 Mar; 74(3):467-73. PubMed ID: 20064608
[TBL] [Abstract][Full Text] [Related]
18. Angiogenic vessel-targeting DDS by liposomalized oligopeptides.
Asai T; Oku N
Methods Mol Biol; 2010; 605():335-47. PubMed ID: 20072892
[TBL] [Abstract][Full Text] [Related]
19. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity.
Zhao Y; Ren W; Zhong T; Zhang S; Huang D; Guo Y; Yao X; Wang C; Zhang WQ; Zhang X; Zhang Q
J Control Release; 2016 Jan; 222():56-66. PubMed ID: 26682502
[TBL] [Abstract][Full Text] [Related]
20. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
Li X; Ding L; Xu Y; Wang Y; Ping Q
Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]